Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
about
Bacteroides: the good, the bad, and the nitty-grittyAerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosisIdentification of novel regulatory small RNAs in Acinetobacter baumanniiThe human milk protein-lipid complex HAMLET sensitizes bacterial pathogens to traditional antimicrobial agentsEfficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysisSecular trends of blood isolates in patients from a rural area population hospitalized in a tertiary center in a small city in GreeceImcroporin, a new cationic antimicrobial peptide from the venom of the scorpion Isometrus maculates.Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in IranDetection and typing of integrons in epidemic strains of Acinetobacter baumannii found in the United KingdomInfections Caused by Acinetobacter baumannii in Recipients of Hematopoietic Stem Cell Transplantation.Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatmentActivity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action.Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.Poly-N-acetyl-β-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections.Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii.Biofilm Formation Caused by Clinical Acinetobacter baumannii Isolates Is Associated with Overexpression of the AdeFGH Efflux Pump.Efflux-mediated antimicrobial resistance.Update on antimicrobial agents: new indications of older agents.What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria?Treatment options for multidrug-resistant bacteria.Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology.Mucroporin, the first cationic host defense peptide from the venom of Lychas mucronatusThe current state of multidrug-resistant gram-negative bacilli in North America.Bacteriophage and their lysins for elimination of infectious bacteria.Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections.Treatment options for multidrug-resistant nonfermenters.Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii.Colistin: an update on the antibiotic of the 21st century.Expert synthesis of the literature to support critical care decision making.Acinetobacter baumannii: A Brief Account of Mechanisms of Multidrug Resistance and Current and Future Therapeutic ManagementClinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter.Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system.Antibiotic resistance and expression of resistance-nodulation-division pump- and outer membrane porin-encoding genes in Acinetobacter species isolated from Canadian hospitals.Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital.In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene.Successful management of nosocomial ventriculitis and meningitis caused by extensively drug-resistant Acinetobacter baumannii in Austria.Emerging and Re-emerging Infectious Diseases in South East Asia.The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor.Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin.
P2860
Q24685642-4A4B5BD7-5508-481A-ABE8-952F42555A23Q24802824-58777FB1-52D2-49B0-9936-4DD20F35B524Q28237546-283FC99B-D67D-47DB-B6B1-C90541C82E32Q28482276-E2861507-B66F-4CF1-8615-35C608489C18Q28539496-DBE0D532-3731-4F48-BD3A-DEB877D2073DQ33241976-899127F5-DE71-47EE-AEF4-8CC93AA3026DQ33447111-E69E3306-36A1-4A51-90B6-80AB07813409Q33833251-98F871AE-1599-4F55-AD14-3F671A207877Q33885182-84684A0F-523E-4119-B33B-5AD28760934DQ33892585-6CB946C2-2FDF-40D2-9A0D-78487AA096EDQ34405889-67C4B57E-8F89-463C-AE95-2721DE4526D4Q34510497-68FDADFC-BB86-4A9C-9C98-DB8C6ABFF831Q34568784-C908B750-A0BF-4B90-AA6D-7F037BC7270EQ35023321-89DC2940-B7B9-44AD-B097-B821B1C9E7F1Q35689459-6B33812F-4596-4131-B3A0-7B1ABE8FE330Q35784520-33C9F3DF-1B9F-4514-A8BE-9A1399BD83E4Q35859953-4139EC59-91B5-4B72-9DE2-5B9F9F40AD54Q36138147-1D803C54-A043-46CF-9186-E8236CBEE45BQ36222046-0A6BCE0B-77C0-482A-846B-C7082DF85752Q36559365-23787B6D-C9FA-4685-926A-7DC9B9263C89Q36607401-B6FC869C-CF1F-461F-8AEA-52367B14F901Q36804312-A360ADFA-9FC4-4C9A-9AD9-0BFA74F805D3Q36949473-487D4CF6-51CC-4368-9792-B74241D880EFQ37069191-F392BB0D-9B0C-4DE8-AB2C-77DFF98E5E39Q37470848-C963C703-5AF4-4A62-8E15-879C2AE99A20Q37557606-F5132427-557E-48C4-A2BD-08A16EB38770Q37700555-ED6C2FDF-7A6B-453B-B475-A25CA4B5B5CBQ37838117-6A73B854-2384-4A1A-9C93-168038101355Q38048852-1B39A5D4-3CC1-45A2-9189-41BC0F4D3652Q38961737-B8C0ABD9-4DB7-4979-8715-F28FEB405129Q39279278-5C38059D-7928-498F-805F-67DA657CE197Q39749477-A90BBEF4-8AC2-42FB-9276-E2A5F0BCA31AQ39922949-E222D977-8F7D-42C8-B645-DCF1EB2EB964Q39938893-FAADFB5F-B84B-4A4A-A54A-0B32028E692AQ40196177-EC307DB0-756D-44D7-9EF4-DBEAD1E90654Q42232084-274D7FB0-EE23-4288-A5E8-CCA317B89C9BQ42233003-11645B6E-21B5-46E8-89CA-25BCE4D23E18Q42365856-931223D1-F828-45F6-AA63-079807545029Q42428390-F90E33FD-5A26-4295-9055-A8C2739338DBQ42537114-2CC305E9-A87D-411C-8908-238276D38F7E
P2860
Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
@ast
Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
@en
type
label
Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
@ast
Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
@en
prefLabel
Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
@ast
Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
@en
P2860
P356
P1476
Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
@en
P2093
Larry H Danziger
Rupali Jain
P2860
P304
P356
10.1345/APH.1D592
P407
P577
2004-07-27T00:00:00Z